Core Points - Northrim BanCorp, Inc. declared a regular quarterly cash dividend of $0.16 per share, payable on December 26, 2025, to shareholders of record as of December 18, 2025 [1] - The current dividend yield is 2.55% based on a stock price of $25.05 per share as of December 4, 2025 [2] - In the third quarter of 2025, Northrim reported a net income of $27.1 million, or $1.20 per diluted share, a significant increase from $11.8 million, or $0.52 per diluted share in the second quarter of 2025, and $8.8 million, or $0.39 per diluted share in the third quarter of the previous year [3] Company Overview - Northrim is the holding company of Northrim Bank, which operates 20 branches throughout Alaska and focuses on understanding Alaska's economy with a "Customer First Service" philosophy [4] - The company also has divisions such as Northrim Funding Services, which operates in factoring and asset-based lending in Washington, and wholly-owned subsidiaries including Sallyport Commercial Finance, LLC, and Residential Mortgage, LLC [4]

Core Insights - Xenon Pharmaceuticals Inc. announced new data on its commitment to epilepsy treatment, including interim 48-month data from the X-TOLE open-label extension study of azetukalner, real-world studies on depression burden, and pre-clinical data for Dravet syndrome [1][2] Group 1: Azetukalner Efficacy and Safety - The interim data from the X-TOLE study showed a monthly seizure frequency reduction of over 90% at 48 months, with a 100% reduction in patients on 1-2 anti-seizure medications (ASMs) at baseline [2][4] - Among participants treated for 48 months, 38.2% achieved at least 12 months of seizure freedom, while 10.7% maintained seizure freedom for 48 months [4] - The long-term safety profile of azetukalner was consistent with that observed during the double-blind period, indicating a favorable tolerability [5] Group 2: Real-World Studies on Depression in Epilepsy - A study found that 80.6% of patients with focal seizures reported depressed mood, highlighting the significant mental health burden among this population [7] - Newly diagnosed epilepsy patients with depression had a higher prevalence of comorbidities and an increased risk of treatment failure, emphasizing the need for tailored treatment strategies [8] - Patients with moderate to severe depression symptoms experienced a lower quality of life and higher healthcare resource utilization, reinforcing the necessity for routine depression screening in epilepsy care [9] Group 3: Pipeline and Future Directions - Xenon is preparing to share Phase 3 data from the X-TOLE2 study in early 2026, which is anticipated to be a significant milestone for the company and the epilepsy community [2] - The company is also advancing early-stage programs targeting potassium and sodium channels for potential pain treatment, indicating a broadening of its therapeutic focus [15]

Fleet Rocket TMS is now integrated with Solvento’s financial solutions platform, enabling direct invoicing and full suite payment capabilities for logistics operatorsHOUSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a logistics management innovation company offering a diverse portfolio of technology-driven solutions, today announced a strategic partnership with Solvento, a leading fintech provider serving the trucking and logistics industry in ...

Core Viewpoint - The company reaffirms its financial strength and strategic progress despite elevated short-selling activity, emphasizing a significant disconnect between its market valuation and intrinsic value [1][2][3]. Financial Position - Total assets exceed US$106.7 million, with cash, cash equivalents, and short-term investments totaling approximately US$53.8 million, and shareholders' equity at around US$56.9 million [3]. - The current market capitalization is approximately US$14 million, representing about 25% of net asset value and less than 30% of cash and short-term investments [3]. Expense Management - Increased operating expenses are attributed to a prolonged shareholder control dispute, which is exceptional and non-recurring, not indicative of operational weakness [4]. - The company has optimized its cost structure and improved the efficiency of strategic capital deployment while maintaining stable operational progress [4]. Income Generation - The company generated over US$3.5 million in interest and investment income during the first nine months, showcasing a resilient financial foundation [5]. Strategic Focus - The company aims to expand higher-margin experiential and live entertainment businesses, advance monetization models, and pursue selective investment opportunities [6]. - With liquidity exceeding US$53 million, the company is positioned to execute its growth strategy without pressure from short-term market fluctuations [6]. Shareholder Guidance - The company advises shareholders to exercise caution regarding unverified commentary and to evaluate based on official disclosures and long-term value rather than short-term price movements [7]. - Management remains confident in delivering sustainable value to long-term shareholders and is committed to transparent communication and disciplined execution [8].

Core Insights - Zorevunersen shows potential as a disease-modifying therapy for Dravet syndrome, demonstrating durable seizure reductions and improvements in cognition, behavior, and quality of life in patients [1][3][4] Clinical Data - Long-term Phase 1/2a and open label extension (OLE) studies indicate significant reductions in seizure frequency and increased seizure-free days for patients treated with zorevunersen alongside standard anti-seizure medicines [1][3][4] - A propensity score weighted analysis revealed that patients receiving zorevunersen experienced statistically significant reductions in major motor seizure frequency at six months, consistent with the ongoing Phase 3 EMPEROR study [5][6] - Improvements in cognition and behavior were observed at 18 months, with several assessments reaching statistical significance [5][6] Mechanism of Action - Analysis of electroencephalogram (EEG) data supports a disease-modifying mechanism of action for zorevunersen, showing dose-dependent effects in decreasing abnormal brain activity associated with Dravet syndrome [2][7] Safety Profile - Zorevunersen has been generally well tolerated, with 30% of patients in Phase 1/2a studies and 53% in OLE studies experiencing treatment-emergent adverse events (TEAEs) [8] - The most common TEAE was CSF protein elevations, occurring in 14% of patients in Phase 1/2a and 45% in OLE studies, with no related clinical manifestations observed [8] Future Directions - The ongoing Phase 3 EMPEROR study aims to further evaluate the efficacy and safety of zorevunersen in children with Dravet syndrome, with a focus on seizure frequency and improvements in behavior and cognition [12] - The collaboration between Biogen and Stoke Therapeutics is expected to advance the development and commercialization of zorevunersen for Dravet syndrome [11][16]

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shareholders rec ...

Core Insights - LZ Technology Holdings Limited has entered into a partnership with Red Dune Capital Holding Limited to establish its regional headquarters in the MENA region and commercialize its smart access control systems and IoT technologies [1][2][4] - This partnership signifies the launch of LZ Technology's global second growth curve, aiming to replicate its successful business model from China in the MENA region [2][4] - The MENA region is experiencing rapid growth in smart-city development and digital infrastructure investment, creating a favorable environment for LZ Technology's expansion [2][4] Company Strategy - The collaboration aims to build a full-scale operational platform in MENA, focusing on smart access control, community-service digitalization, and integrated business-service ecosystems [2][3] - LZ Technology plans to leverage Red Dune's extensive local networks and capital capabilities to accelerate its expansion in the Middle East [3][4] - The goal is to create "another LZ Technology" in the MENA region, establishing a strong regional presence and a second global growth engine [4] Market Potential - The MENA region is witnessing strong growth in urban digital governance, property management modernization, and digital public service upgrades, indicating a robust market potential for LZ Technology [2][4] - LZ Technology intends to progressively expand into key markets such as Saudi Arabia, Qatar, Kuwait, and Egypt, aiming to build a region-wide smart-community digital network [4] Company Overview - LZ Technology operates primarily in three verticals: Smart Community, Out-of-Home Advertising, and Local Life, providing intelligent access control and safety management systems across thousands of residential communities in China [5] - The Out-of-Home Advertising division offers multi-channel advertising solutions through a vast network of monitors in approximately 120 cities in China [5]

Core Insights - Edible Garden AG Incorporated has launched its Pickle Party™ product line in King Kullen supermarkets, enhancing its presence in the New York Metro region as demand for clean-label foods grows [1][3]. Product Overview - Pickle Party™ is the world's first functional pickle line, featuring raw, refrigerated, fermented, Kosher, and Non-GMO products made through traditional fermentation methods that support digestive wellness [2]. - The product line includes a variety of pickles and krauts with unique flavor profiles, free from artificial preservatives, stabilizers, and added sugars, aligning with the company's commitment to better-for-you foods [2]. Market Strategy - The partnership with King Kullen, a well-established supermarket chain, reflects Edible Garden's strategy to collaborate with respected regional grocers that prioritize fresh, responsibly sourced foods [3]. - The introduction of Pickle Party™ is positioned to meet the growing consumer interest in fermented and health-forward products, thereby strengthening the company's market presence [3]. Company Background - Edible Garden is a leader in controlled environment agriculture (CEA), providing sustainable, locally grown organic produce through its Zero-Waste Inspired® farming model, available in over 5,000 retail locations [4]. - The company utilizes advanced safety protocols, sustainable packaging, and patented technologies to optimize growing conditions and reduce environmental impact [5]. Additional Offerings - In addition to Pickle Party™, Edible Garden markets a range of nutrition and specialty food products, including plant and whey protein powders, and gourmet sauces [6][7].

Core Insights - Toro Corp. reported its financial results for the third quarter and nine months ended September 30, 2025, highlighting a stable performance despite some declines in revenue and net income compared to the previous year [1][2]. Financial Performance - Third Quarter - Total vessel revenues from continuing operations increased to $5.4 million, a 1.9% increase from $5.3 million in the same period of 2024 [5][6]. - Net income from continuing operations rose to $1.3 million, reflecting a 30% increase from $1.0 million in the third quarter of 2024 [5][6]. - EBITDA from continuing operations was $1.6 million, compared to a loss of $0.1 million in the same period last year [5][6]. - The average Daily TCE Rate improved to $13,363 from $11,426 in the same period of 2024 [6][41]. Financial Performance - Nine Months - Total vessel revenues from continuing operations decreased to $15.0 million, a 12.8% decline from $17.2 million for the nine months ended September 30, 2024 [5][28]. - Net income from continuing operations was $4.2 million, down 6.7% from $4.5 million in the same period last year [5][28]. - Net income overall dropped significantly to $4.3 million, an 82.2% decrease from $24.2 million for the nine months ended September 30, 2024 [5][28]. - EBITDA for the nine months was $3.8 million, up from $1.7 million in the same period of 2024 [5][28]. Operational Developments - The company acquired two MR tanker vessels and sold two LPG carriers during the third quarter, indicating ongoing fleet management activities [4]. - The spin-off of the Handysize tanker segment to Robin Energy Ltd. was completed on April 14, 2025 [5]. Cash Flow and Liquidity - Cash position decreased by $12.1 million to $25.1 million as of September 30, 2025, primarily due to net operating cash flows used in continuing operations and financing activities [15][38]. - The company made a capital contribution of $10.4 million to Robin in connection with the spin-off [15]. Recent Business Developments - On October 15, 2025, Toro received dividends from Castor and Robin, amounting to $1.25 million and $0.125 million, respectively [16]. - An "at-the-market" offering agreement was established on November 13, 2025, allowing the company to sell common shares valued up to $12.5 million for various corporate purposes [18].

Core Insights - Jeffs' Brands Ltd has entered into a distribution agreement with Scanary Ltd, marking its strategic entry into the global homeland-security sector [1][2] Company Overview - Jeffs' Brands is a data-driven e-commerce company focused on transforming products into market leaders through advanced technology and management insights [4] Agreement Details - KeepZone AI Inc., a subsidiary of Jeffs' Brands, will market and distribute Scanary's AI-radar screening systems, which can scan up to 25,000 people per hour without stopping [2] - The agreement includes a one-time payment of $1 million to Scanary, payable in five monthly installments of $200,000 [3] - Scanary will provide a free demonstration unit and technical support for pre-sales activities [3] Market Potential - The security scanning equipment market was valued at over $11.4 billion in 2022 and is expected to grow at a CAGR of over 7% from 2023 to 2032 [3] Distribution Rights - KeepZone has exclusive distribution rights for the systems in Canada, Germany, and the UAE for an initial 24-month period, extendable upon achieving a purchase target of 20 systems [6] - Non-exclusive distribution rights are granted in Spain and Italy [6]